Clinical characteristics of each of the nine Crohn’s disease (CD) patients treated with Infliximab who developed neoplasia during follow up
| Pt No | Sex | CD site | CD type | CD duration (y) | Type of neoplasia | Age at neoplasia diagnosis (outcome) | ISS (months) | No of infusions (schedule) | Time since IFX (months) | Time since ISS (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| ISS, immunosuppressants; IFX, Infliximab; F, female; M, male; I, ileum; C, colon; I-C, ileum-colon; C, colon; L, luminal; F, fistulising; AZA, azathioprine; Thalid, thalidomide; MTX, methotrexate; ND, not done. | ||||||||||
| 1 | M | I-C | F | 23 | Cholangiocarcinoma | 48 Deceased | AZA (5) | 3 acute | 6 | 5 |
| 2 | F | I-C | L | 23 | Anal carcinoma | 70 Deceased | Thalid (4) | 9 on demand | 45 | 96 |
| 3 | F | I-C | F | 24 | Anal carcinoma | 41 Deceased | ND | 2 on demand | 6 | ND |
| 4 | F | C | L | 39 | Breast cancer | 50 Remission | MTX (36) | 6 on demand | 24 | 36 |
| 5 | F | I | L | 39 | Breast cancer | 60 Remission | ND | 4 on demand | 15 | ND |
| 6 | F | I-C | F | 6 | Breast cancer | 40 Remission | AZA (52) | 6 maintenance | 33 | 52 |
| 7 | F | C | L | 13 | Leukaemia | 45 Lost to follow up | AZA (24) | 4 maintenance | 12 | 144 |
| 8 | M | I | L | 18 | Basalioma | 61 Remission | AZA (36) | 11 maintenance | 18 | 24 |
| 9 | F | I-C | F | 5 | Laryngeal carcinoma | 53 Remission | AZA (48) | 2 on demand | 38 | 40 |